New mint on the block – Fresh hope for IBS treatment?

Irritable bowel syndrome (IBS) is one of the most prevalent and expensive conditions in gastroenterology, incurring high costs for health systems and patients alike.1, 2 The minimum direct and indirect costs related to IBS are estimated to range from 6 to 8 billion euros per year in Europe.3 Despite its high prevalence, we are only beginning to understand the multifactorial pathogenesis of IBS, and treatment remains symptom-based and challenging...